Phenotypic and molecular differences between giant‐cell tumour of soft tissue and its bone counterpart
- 29 June 2017
- journal article
- Published by Wiley in Histopathology
- Vol. 71 (3) , 453-460
Abstract
Aims: Giant‐cell tumour (GCT) of soft tissue (GCT‐ST) is a primary soft tissue neoplasm that is histologically similar to GCT of bone (GCT‐B). Recently, it has been reported that >90% of GCT‐Bs have a driver mutation in the H3F3A gene. As the relationship between GCT‐ST and GCT‐B is unclear, the aim of this study was to compare a series of GCT‐STs and GCT‐Bs with regard to the presence of H3F3A mutations and several immunophenotypic markers.Methods and results: Eight GCT‐STs were retrieved from our institutional archives. Fifteen GCT‐Bs served as controls. Direct sequencing for H3F3A mutations in coding regions between codons 1 and 42, including the hotspot codons (28, 35, and 37), was performed on DNA extracted from formalin‐fixed paraffin‐embedded tissue. Tumours were studied immunohistochemically for the expression of CD14, CD33, RANKL, RANK, p63, and the osteoblastic markers SATB2 and RUNX2. None of the seven GCT‐STs that could be analysed showed H3F3A mutations, whereas 14 GCT‐Bs (93.3%) were mutated. All eight GCT‐STs were positive for RANK and RUNX2, whereas RANKL and SATB2 were detected in only two cases (25%). CD14 was detected only in mononuclear elements, whereas multinucleated giant cells and a proportion of the mononuclear population expressed CD33. Few mononuclear cells of GCT‐STs expressed p63. In comparison, GCT‐Bs showed higher expression of p63 (14 of 15 cases with >50% of positive mononuclear cells), RANKL, and SATB2, whereas CD14, CD33, RANK and RUNX2 were similarly expressed.Conclusions: Although GCT‐ST and GCT‐B are similar in histological appearance, our results indicate that they are immunophenotypically and genetically distinct.Keywords
This publication has 28 references indexed in Scilit:
- Targeting the Giant Cell Tumor Stromal Cell: Functional Characterization and a Novel Therapeutic StrategyPLOS ONE, 2013
- Giant cell tumor of bone: A basic science perspectiveBone, 2013
- miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2Journal of Cell Biology, 2012
- Roles of SATB2 in Osteogenic Differentiation and Bone RegenerationTissue Engineering Part A, 2011
- COLD-PCR: improving the sensitivity of molecular diagnostics assaysExpert Review of Molecular Diagnostics, 2011
- A network connecting Runx2, SATB2, and the miR-23a∼27a∼24-2 cluster regulates the osteoblast differentiation programProceedings of the National Academy of Sciences, 2010
- The Use of COLD-PCR and High-Resolution Melting Analysis Improves the Limit of Detection of KRAS and BRAF Mutations in Colorectal CancerThe Journal of Molecular Diagnostics, 2010
- Histogenetic Characterization of Giant Cell Tumor of BoneClinical Orthopaedics and Related Research, 2008
- SATB2 Is a Multifunctional Determinant of Craniofacial Patterning and Osteoblast DifferentiationCell, 2006
- Osteoblast lineage properties in giant cell tumors of boneJournal of Orthopaedic Science, 2005